002412 汉森制药
交易中 12-20 14:10:33
资讯
新帖
简况
汉森制药(002412)11月29日股东户数2.64万户,较上期减少0.21%
证券之星 · 12-13
汉森制药(002412)11月29日股东户数2.64万户,较上期减少0.21%
汉森制药(002412)11月29日股东户数2.64万户,较上期减少0.21%
证券之星 · 12-04
汉森制药(002412)11月29日股东户数2.64万户,较上期减少0.21%
汉森制药(002412)10月31日股东户数2.65万户,较上期减少1.51%
证券之星 · 11-27
汉森制药(002412)10月31日股东户数2.65万户,较上期减少1.51%
图解汉森制药三季报:第三季度单季净利润同比增58.63%
证券之星 · 10-29
图解汉森制药三季报:第三季度单季净利润同比增58.63%
汉森制药(002412.SZ)发布前三季度业绩,净利润1.31亿元,同比增长19.15%
智通财经 · 10-28
汉森制药(002412.SZ)发布前三季度业绩,净利润1.31亿元,同比增长19.15%
汉森制药最新公告:获得恩格列净片药品注册证书
证券之星 · 10-23
汉森制药最新公告:获得恩格列净片药品注册证书
汉森制药(002412.SZ)获恩格列净片药品注册证书
智通财经 · 10-23
汉森制药(002412.SZ)获恩格列净片药品注册证书
汉森制药:10月10日接受机构调研,投资者参与
证券之星 · 10-10
汉森制药:10月10日接受机构调研,投资者参与
汉森制药(002412)2024年中报简析:营收净利润同比双双增长,应收账款上升
证券之星 · 08-15
汉森制药(002412)2024年中报简析:营收净利润同比双双增长,应收账款上升
汉森制药(002412)8月13日主力资金净卖出330.12万元
证券之星 · 08-14
汉森制药(002412)8月13日主力资金净卖出330.12万元
图解汉森制药中报:第二季度单季净利润同比增18.62%
证券之星 · 08-14
图解汉森制药中报:第二季度单季净利润同比增18.62%
汉森制药(002412.SZ)发布上半年业绩,净利润1亿元,增长10.84%
智通财经 · 08-13
汉森制药(002412.SZ)发布上半年业绩,净利润1亿元,增长10.84%
汉森制药最新公告:2024年上半年净利润1亿元 同比增长10.84%
证券之星 · 08-13
汉森制药最新公告:2024年上半年净利润1亿元 同比增长10.84%
汉森制药最新公告:药品生产许可证变更
证券之星 · 08-08
汉森制药最新公告:药品生产许可证变更
汉森制药:如有分红派息计划,公司将会按照相关规定履行信息披露义务,敬请关注公司公告
证券之星 · 07-01
汉森制药:如有分红派息计划,公司将会按照相关规定履行信息披露义务,敬请关注公司公告
汉森制药:截至2024年5月31日,公司含信用账户合并股东名册的股东总数为:27529人
证券之星 · 06-26
汉森制药:截至2024年5月31日,公司含信用账户合并股东名册的股东总数为:27529人
汉森制药:利胆止痛胶囊是子公司永孜堂的独家剂型产品,为国家医保协议期内谈判药品
证券之星 · 06-20
汉森制药:利胆止痛胶囊是子公司永孜堂的独家剂型产品,为国家医保协议期内谈判药品
加载更多
公司概况
公司名称:
湖南汉森制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-05-25
主营业务:
湖南汉森制药股份有限公司是一家从事传统中成药制剂、化学药、医用制剂的研发、生产和销售的企业。其主要产品包括了四磨汤口服液和胶囊、复方氨酚烷胺片、碘海醇注射液等。公司的主要产品四磨汤口服液为国家医保目录乙类产品,是公司独家生产品种,已获批中药保护品种,为“湖南省高新技术产品”“湖南省生物医药产业链重点品种”并被授予“湖南省产品质量奖”。
发行价格:
35.80
{"stockData":{"symbol":"002412","market":"SZ","secType":"STK","nameCN":"汉森制药","latestPrice":6.33,"timestamp":1734675033000,"preClose":6.26,"halted":0,"volume":7177570,"delay":0,"floatShares":498000000,"shares":503000000,"eps":0.4492,"marketStatus":"交易中","marketStatusCode":2,"change":0.07,"latestTime":"12-20 14:10:33","open":6.26,"high":6.42,"low":6.25,"amount":45329600,"amplitude":0.0272,"askPrice":6.34,"askSize":56,"bidPrice":6.33,"bidSize":160,"shortable":0,"etf":0,"ttmEps":0.4492,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1734678000000},"adr":0,"adjPreClose":6.26,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":6.89,"lowLimit":5.63,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":503200000,"pbRate":1.5,"roa":"--","roe":"6.43%","epsLYR":0.4074,"committee":0.03578,"marketValue":3185000000,"floatMarketCap":3151000000,"peRate":14.091718,"changeRate":0.0112,"turnoverRate":0.0144,"status":0},"requestUrl":"/m/hq/s/002412","defaultTab":"news","newsList":[{"id":"2491534943","title":"汉森制药(002412)11月29日股东户数2.64万户,较上期减少0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491534943","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491534943?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:03","pubTimestamp":1734080588,"startTime":"0","endTime":"0","summary":"证券之星消息,近日汉森制药披露,截至2024年11月29日公司股东户数为2.64万户,较10月31日减少56.0户,减幅为0.21%。在中药行业个股中,汉森制药股东户数低于行业平均水平,截至11月29日,中药行业平均股东户数为5.03万户。从股价来看,2024年10月31日至2024年11月29日,汉森制药区间涨幅为5.54%,在此期间股东户数减少56.0户,减幅为0.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300029535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","002412","BK0239"],"gpt_icon":0},{"id":"2488549311","title":"汉森制药(002412)11月29日股东户数2.64万户,较上期减少0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488549311","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488549311?lang=zh_cn&edition=full","pubTime":"2024-12-04 17:03","pubTimestamp":1733303021,"startTime":"0","endTime":"0","summary":"证券之星消息,近日汉森制药披露,截至2024年11月29日公司股东户数为2.64万户,较10月31日减少56.0户,减幅为0.21%。在中药行业个股中,汉森制药股东户数低于行业平均水平,截至11月29日,中药行业平均股东户数为5.03万户。从股价来看,2024年10月31日至2024年11月29日,汉森制药区间涨幅为5.54%,在此期间股东户数减少56.0户,减幅为0.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400029523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","002412","BK0239"],"gpt_icon":0},{"id":"2486848859","title":"汉森制药(002412)10月31日股东户数2.65万户,较上期减少1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486848859","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486848859?lang=zh_cn&edition=full","pubTime":"2024-11-27 17:03","pubTimestamp":1732698194,"startTime":"0","endTime":"0","summary":"证券之星消息,近日汉森制药披露,截至2024年10月31日公司股东户数为2.65万户,较9月30日减少406.0户,减幅为1.51%。在中药行业个股中,汉森制药股东户数低于行业平均水平,截至10月31日,中药行业平均股东户数为5.03万户。从股价来看,2024年9月30日至2024年10月31日,汉森制药区间跌幅为0.16%,在此期间股东户数减少406.0户,减幅为1.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112700027796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","BK0028","002412"],"gpt_icon":0},{"id":"2479430806","title":"图解汉森制药三季报:第三季度单季净利润同比增58.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479430806","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479430806?lang=zh_cn&edition=full","pubTime":"2024-10-29 01:38","pubTimestamp":1730137122,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药2024年三季报显示,公司主营收入6.94亿元,同比上升1.44%;归母净利润1.31亿元,同比上升19.15%;扣非净利润1.23亿元,同比上升19.14%;其中2024年第三季度,公司单季度主营收入2.14亿元,同比上升0.5%;单季度归母净利润3025.9万元,同比上升58.63%;单季度扣非净利润2805.81万元,同比上升65.15%;负债率14.33%,投资收益474.02万元,财务费用121.13万元,毛利率75.13%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900001107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412"],"gpt_icon":0},{"id":"2478643811","title":"汉森制药(002412.SZ)发布前三季度业绩,净利润1.31亿元,同比增长19.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478643811","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478643811?lang=zh_cn&edition=full","pubTime":"2024-10-28 23:21","pubTimestamp":1730128871,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汉森制药(002412.SZ)发布2024年三季度报告,前三季度,公司实现营业收入6.94亿元,同比增长1.44%。归属于上市公司股东的净利润1.31亿元,同比增长19.15%。归属于上市公司股东的扣除非经常性损益的净利润1.23亿元,同比增长19.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002412"],"gpt_icon":0},{"id":"2477051301","title":"汉森制药最新公告:获得恩格列净片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2477051301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477051301?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:10","pubTimestamp":1729678208,"startTime":"0","endTime":"0","summary":"汉森制药公告,公司近日收到国家药监局核准签发的化学药品“恩格列净片”的《药品注册证书》。该药品适用于治疗2型糖尿病。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300031185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0039","002412"],"gpt_icon":0},{"id":"2477830997","title":"汉森制药(002412.SZ)获恩格列净片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2477830997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477830997?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:08","pubTimestamp":1729678080,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汉森制药(002412.SZ)公告,公司近日收到国家药品监督管理局核准签发的化学药品“恩格列净片”的《药品注册证书》,该药品适用于治疗2型糖尿病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","002412","BK0239","BK0039"],"gpt_icon":0},{"id":"2474745487","title":"汉森制药:10月10日接受机构调研,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2474745487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474745487?lang=zh_cn&edition=full","pubTime":"2024-10-10 21:21","pubTimestamp":1728566515,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年10月10日汉森制药发布公告称公司于2024年10月10日接受机构调研。汉森制药2024年中报显示,公司主营收入4.8亿元,同比上升1.86%;归母净利润1.0亿元,同比上升10.84%;扣非净利润9485.71万元,同比上升10.07%;其中2024年第二季度,公司单季度主营收入2.26亿元,同比上升2.22%;单季度归母净利润4222.93万元,同比上升18.62%;单季度扣非净利润3965.63万元,同比上升17.88%;负债率15.31%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101000038249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","BK0239","002412"],"gpt_icon":0},{"id":"2459340094","title":"汉森制药(002412)2024年中报简析:营收净利润同比双双增长,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2459340094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459340094?lang=zh_cn&edition=full","pubTime":"2024-08-15 06:06","pubTimestamp":1723673168,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期汉森制药发布2024年中报。截至本报告期末,公司营业总收入4.8亿元,同比上升1.86%,归母净利润1.0亿元,同比上升10.84%。按单季度数据看,第二季度营业总收入2.26亿元,同比上升2.22%,第二季度归母净利润4222.93万元,同比上升18.62%。本报告期汉森制药应收账款上升,应收账款同比增幅达30.83%。合同负债变动幅度为-86.96%,原因:报告期末收到的与销货合同相关的款项减少。其他应付款变动幅度为42.68%,原因:报告期末业务员业务费用暂未支付。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081500010549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412"],"gpt_icon":0},{"id":"2459610381","title":"汉森制药(002412)8月13日主力资金净卖出330.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459610381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459610381?lang=zh_cn&edition=full","pubTime":"2024-08-14 09:27","pubTimestamp":1723598856,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月13日收盘,汉森制药报收于5.66元,下跌1.22%,换手率1.16%,成交量5.79万手,成交额3269.29万元。近5日资金流向一览见下表:汉森制药融资融券信息显示,融资方面,当日融资买入308.73万元,融资偿还447.33万元,融资净偿还138.6万元。汉森制药主营业务:公司是一家集研发、生产、销售为一体的医药制造企业,生产中药制剂为主,化学药为辅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400016624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002412","BK0239","BK0039"],"gpt_icon":0},{"id":"2459256187","title":"图解汉森制药中报:第二季度单季净利润同比增18.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459256187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459256187?lang=zh_cn&edition=full","pubTime":"2024-08-14 01:28","pubTimestamp":1723570112,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药2024年中报显示,公司主营收入4.8亿元,同比上升1.86%;归母净利润1.0亿元,同比上升10.84%;扣非净利润9485.71万元,同比上升10.07%;其中2024年第二季度,公司单季度主营收入2.26亿元,同比上升2.22%;单季度归母净利润4222.93万元,同比上升18.62%;单季度扣非净利润3965.63万元,同比上升17.88%;负债率15.31%,投资收益1181.01万元,财务费用91.82万元,毛利率74.61%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400001624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412"],"gpt_icon":0},{"id":"2459976285","title":"汉森制药(002412.SZ)发布上半年业绩,净利润1亿元,增长10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459976285","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459976285?lang=zh_cn&edition=full","pubTime":"2024-08-13 19:05","pubTimestamp":1723547144,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汉森制药(002412.SZ)发布2024年半年度报告,该公司营业收入为4.8亿元,同比增长1.86%。归属于上市公司股东的净利润为1亿元,同比增长10.84%。归属于上市公司股东的扣除非经常性损益的净利润为9485.71万元,同比增长10.07%。基本每股收益为0.1997元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1163636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002412"],"gpt_icon":0},{"id":"2459897989","title":"汉森制药最新公告:2024年上半年净利润1亿元 同比增长10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459897989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459897989?lang=zh_cn&edition=full","pubTime":"2024-08-13 18:59","pubTimestamp":1723546798,"startTime":"0","endTime":"0","summary":"汉森制药发布2024年半年度报告,报告期内,公司实现营业收入4.80亿元,同比增长1.86%;归属于上市公司股东的净利润1.00亿元,同比增长10.84%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081300037154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412"],"gpt_icon":0},{"id":"2457127233","title":"汉森制药最新公告:药品生产许可证变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2457127233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457127233?lang=zh_cn&edition=full","pubTime":"2024-08-08 22:21","pubTimestamp":1723126884,"startTime":"0","endTime":"0","summary":"汉森制药公告,公司近期完成了《药品生产许可证》的变更登记并取得了湖南省药品监督管理局核发的《药品生产许可证》,本次变更的事项为:新增生产范围“第二类精神药品(氢溴酸右美沙芬颗粒)”。其他内容不变。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080800044331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0039","BK0028","BK0239"],"gpt_icon":0},{"id":"2448958719","title":"汉森制药:如有分红派息计划,公司将会按照相关规定履行信息披露义务,敬请关注公司公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2448958719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448958719?lang=zh_cn&edition=full","pubTime":"2024-07-01 19:00","pubTimestamp":1719831635,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)07月01日在投资者关系平台上答复投资者关心的问题。投资者:汉森制药七月份有没有有分红计划?汉森制药董秘:投资者您好,如有分红派息计划,公司将会按照相关规定履行信息披露义务,敬请关注公司公告。感谢您的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100024319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0028","BK0239"],"gpt_icon":0},{"id":"2446836643","title":"汉森制药:截至2024年5月31日,公司含信用账户合并股东名册的股东总数为:27529人","url":"https://stock-news.laohu8.com/highlight/detail?id=2446836643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446836643?lang=zh_cn&edition=full","pubTime":"2024-06-26 19:00","pubTimestamp":1719399648,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)06月26日在投资者关系平台上答复投资者关心的问题。投资者:请问截止到2024年6月20日公司收盘股东人数是多少?谢谢汉森制药董秘:投资者您好,截至2024年5月31日,公司含信用账户合并股东名册的股东总数为:27529人。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600037459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0039","BK0028","BK0239"],"gpt_icon":0},{"id":"2444158292","title":"汉森制药:利胆止痛胶囊是子公司永孜堂的独家剂型产品,为国家医保协议期内谈判药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2444158292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444158292?lang=zh_cn&edition=full","pubTime":"2024-06-20 19:00","pubTimestamp":1718881236,"startTime":"0","endTime":"0","summary":"考虑到未来通胀预期,公司大部分产品价格偏低,近几年市场日用药费用20-30元品种大多增长迅速,公司领导是否有思考和应对措施,建议把产品提价工作作为公司目前紧急第一要务,把所有独家产品日用药费用提价到20元以上,请把建议反馈至董事会汉森制药董秘:利胆止痛胶囊是子公司永孜堂的独家剂型产品,为国家医保协议期内谈判药品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000035355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0039","002412"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-05-25","address":"湖南省益阳市赫山区银城大道2688号","stockEarnings":[{"period":"1week","weight":-0.0712},{"period":"1month","weight":0.0146},{"period":"3month","weight":0.2396},{"period":"6month","weight":0.1723},{"period":"1year","weight":-0.0821},{"period":"ytd","weight":-0.0767}],"companyName":"湖南汉森制药股份有限公司","boardCode":"AI0027","perCapita":"18827股","boardName":"医药制造业","registeredCapital":"50320万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 湖南汉森制药股份有限公司是一家从事传统中成药制剂、化学药、医用制剂的研发、生产和销售的企业。其主要产品包括了四磨汤口服液和胶囊、复方氨酚烷胺片、碘海醇注射液等。公司的主要产品四磨汤口服液为国家医保目录乙类产品,是公司独家生产品种,已获批中药保护品种,为“湖南省高新技术产品”“湖南省生物医药产业链重点品种”并被授予“湖南省产品质量奖”。","serverTime":1734675041883,"listedPrice":35.8,"stockholders":"26442人(较上一季度减少0.21%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汉森制药,002412,汉森制药股票,汉森制药股票老虎,汉森制药股票老虎国际,汉森制药行情,汉森制药股票行情,汉森制药股价,汉森制药股市,汉森制药股票价格,汉森制药股票交易,汉森制药股票购买,汉森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}